Challenges in Biosimilars Pharmacovigilance

This session of the Biosimilars 2018 looks into the future and FDA initiatives that have already been announced to include enhanced tracking and follow-up of post market issues, planned improvements in AERS, and pilots of new post market drug-monitoring strategies. Current challenges in pharmacovigilance, Adverse drug reactions with pharmaceutical products, Biosimilar guidelines for pharmacovigilance practice and pharmacoepidemiology are the points that shall be laid emphasis in this session.

 

  • Detection and evaluation of drug safety signals
  • Role of pharma industries in the improvement of pharmacovigilance system
  • Adverse drug reactions with biologics and biosimilar products
  • Current problems in biosimilar pharmacovigilance

Related Conference of Challenges in Biosimilars Pharmacovigilance

Challenges in Biosimilars Pharmacovigilance Conference Speakers